First-line chemotherapy in metastatic colorectal cancer: New approaches and therapeutic algorithms. Always hit hard first?

Current Opinion in Oncology

Volumn 20, Issue 4, 2008, Pages 459-465

  Loupakis, Fotios ^a,b   Masi, Gianluca ^a   Vasile, Enrico ^a,b   Falcone, Alfredo ^a,b  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Liver lung resection; Neoadjuvant

Indexed keywords

CAPECITABINE; CYTOTOXIC AGENT; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AGED; ALGORITHM; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; DETERIORATION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LIVER FAILURE; LIVER METASTASIS; MEDICAL DECISION MAKING; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; COLORECTAL TUMOR; LIVER TUMOR; LUNG TUMOR; PATHOLOGY;

ALGORITHMS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS;

EID: 47249124557     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32830218ea     Document Type: Review

References (48)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-592.
2. Saunders M, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006; 95:131-138.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-1047.
4. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
5. Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23:4856-4865.
6. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
7. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
8. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670-1676. A phase III randomized trial which demonstrates that the FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favourable prognostic characteristics.
9. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorour-acil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94:798-805.
10. •] that demonstrate the equivalence of staged strategies and up-front combinations in selected metastatic colorectal cancer patients.
11. •] that demonstrate the equivalence of staged strategies and up-front combinations in selected metastatic colorectal cancer patients.
12. Bouché O, Castaing M, Etienne P, et al. Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007; 25:4069 (abstract).
13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
14. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007; 25:4028 (abstract).
15. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23:3706-3712.
16. Van Cutsem E, Nowascki M, Lang I, Cascinu S. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007; 25:4000 (abstract).
17. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23:7125-7134.
18. Wicherts DA, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol 2007; 33 (Suppl 2):S42-S51.
19. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24:4976-4982.
20. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 2002; 20:1499-1505.
21. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German cooperative on liver metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228: 756-762.
22. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-2048.
23. Mitry E, Fields A, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. J Clin Oncol 2006 ASCO Annual Meeting Proceedings 2006; 24:3524 (abstract).
24. Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204:753-761; discussion 761-753.
25. Kokudo N, Hasegawa K, Makuuchi M. Control arm for surgery alone is needed but difficult to obtain in randomized trials for adjuvant chemotherapy after liver resection for colorectal metastases. J Clin Oncol 2007; 25:1299-1300; author reply 1300.
26. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase, III, study 40 983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases [abstract]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007; 25:LBA5. First report of a randomized trial demonstrating the superiority in terms of PFS of perioperative FOLFOX in patients with metastases confined to the liver deemed initially resectable.
27. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240:1052-1061; discussion 1061-1054.
28. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-318; discussion 318-321.
29. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644-657; discussion 657-648.
30. Masi G, Cupini S, Marcucci L, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006; 13:58-65.
31. •] demonstrate the possibility of bringing initially unresectable metastatic disease to resectability reporting survival results that favourably compare to those of patients resectable ab initio.
32. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-669.
33. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311-1319.
34. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
35. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multi-center study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-4875.
36. Masi G, Bursi S, Loupakis F, et al. Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases [abstract]. Eur J Cancer, 2007 ECCO 14 Meeting Proceedings 2007; 5:242.
37. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460-466.
38. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065-2072.
39. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24:4983-4990.
40. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243:1-7.
41. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939-3945.
42. Sorbye H, Kohne CH, Sargent DJ, Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. Ann Oncol 2007; 18:1666-1672.
43. Schmoll HJ, Sargent D. CAIRO and FOCUS (author's reply). Lancet 2007; 370:1905-1905.
44. Goldberg RM, Kohne C, Seymour MT, et al. A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6286 patients (pts) with metastatic colorectal cancer (MCRC) [abstract]. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007; 25:4011. Retrospective demonstration of the superiority of combination chemotherapy in the treatment of poor performance status metastatic colorectal cancer patients.
45. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22:1209-1214.
46. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23:9441-9442.
47. Labianca R, Floriani I, Cortesi E, et al. Alternating versus continuous 'FOLFIRI' in advanced colorectal cancer (ACC): A randomized 'GISCAD' trial [abstract]. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings 2006; 24:3505.
48. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study [abstract]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 2007; 25:4013. These studies explore the possibility of discontinuing first-line treatment offering patients short periods off treatment thus reducing side effects. First results seem to be conflicting and such strategies should be further investigated.